CAR T-Cell Therapy in Multiple Myeloma : Episode 6
Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
Panelists discuss how to monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients receiving this therapy and how to collaborate with the CAR T-cell therapy team during the treatment phase, emphasizing the most critical aspects of patient care at this stage.
EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment
EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges
EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
Now Viewing
EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience
EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy
EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
How do you monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients who receive this therapy?
Dr Castaneda: Ask Jammie:
How do you collaborate with the CAR T-cell therapy team during the treatment phase, and what aspects of patient care are most critical at this stage?
Recent Videos
Related Content
